Revvity, Inc. · NYSE:RVTY
Revvity — Q3 2024 Earnings Presentation
9 slides from Revvity's earnings presentation, Nov 4, 2024
Slide 1: Third Quarter 2024 Earnings
Third Quarter 2024 Earnings November 4, 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Strong Diagnostics Launched two new A.I. based performance and return to New Corporate HQ growth in Life Science software offerings Reagents Investor Day - November 21st Launched new Strong synergy realization APOE genotype assay in EU & Cash flow
Slide 4: 3Q24 Revenue Highlights
3Q24 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -DD ~ Flat +MSD $0.7 B -LSD +LSD $0.7 B +HSD $0.7 B +LSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our
Slide 5: 3Q24 Financial Results
3Q24 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $684M 28.3% $1.28 $135M +2% y/y +80bps y/y +9% y/y $427M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI +2% | M&A: 0% | FX: 0% 61.7% | +60bps y/y 15.3% 100% Adj. Net Interest & Other: Excludes AE
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -3% Organic Growth 34.2% -LDD -290bps y/y Reported: -2% | M&A: 0% | FX: 0% $301 M • -LSD decline from both Pharma/Biotech and Academic/Gov’t +MSD 3Q24 revenue • -Low-teens instruments decline driven by China; +MSD growth
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS 5% Organic Growth 26.5% Reported: 6% | M&A: 0% | FX: 0% +390 bps y/y +HSD +MSD $383 M • +MSD ImmunoDX globally 3Q24 revenue • +HSD Reproductive Health both globally and in China -LSD • -LSD Applied Genomi
Slide 8: 2024 Financial Guidance
2024 Financial Guidance REVENUE $2.75B - $2.77B Reported: 0% to 1% Organic: 0% to 1% FX: 0%, M&A: 0% ADJUSTED OP. MARGIN 28.0-28.5% ADJUSTED EPS $4.83 - $4.87 Adj. Net interest expense, other: ~$43M Adjusted tax rate: ~19% Average diluted share count: 123.0M 8
Slide 9: Revvity.com
Revvity.com